Filing Details

Accession Number:
0001127602-13-017085
Form Type:
4
Zero Holdings:
No
Publication Time:
2013-05-16 15:44:26
Reporting Period:
2013-05-14
Filing Date:
2013-05-16
Accepted Time:
2013-05-16 15:44:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
912183 Cubist Pharmaceuticals Inc CBST Pharmaceutical Preparations (2834) 223192085
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1219016 W Michael Bonney 65 Hayden Avenue
Lexington MA 02421
Chief Executive Officer Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2013-05-14 6,250 $0.00 161,897 No 4 M Direct
Common Stock Disposition 2013-05-15 2,979 $48.41 158,918 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Restricted Stock Units Disposition 2013-05-14 6,250 $0.00 6,250 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
6,250 2011-05-14 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 6,603 Indirect 401(k) Plan
Common Stock 600 Indirect Trusts
Footnotes
  1. Sold pursuant to a 10(b)5-1 Plan
  2. Shares were sold to cover tax withholding obligations incurred in connection with the vesting of Restricted Stock Units.
  3. This transaction was executed in multiple trades at prices ranging from $48.2350 to $48.7300. The price reported in the table reflects the weighted average sale price. The reporting person undertakes to privde upon request to the SEC staff, the issuer or a secruity holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. Each restricted stock unit represents a contingent right to receive one share of Cubist common stock for no consideration.
  5. The restricted stock units vest 25% annually over a four-year period, with the first 25% vesting one year after the grant date. The restricted stock units do not expire.